Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

GRISTINA, Valerio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.295
EU - Europa 2.537
AS - Asia 2.117
Continente sconosciuto - Info sul continente non disponibili 417
SA - Sud America 367
AF - Africa 88
OC - Oceania 10
Totale 8.831
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.162
SG - Singapore 877
RU - Federazione Russa 833
IT - Italia 717
CN - Cina 434
BR - Brasile 304
DE - Germania 258
VN - Vietnam 200
HK - Hong Kong 188
FI - Finlandia 162
PL - Polonia 147
FR - Francia 135
BD - Bangladesh 102
GB - Regno Unito 97
CA - Canada 73
JP - Giappone 70
IN - India 67
NL - Olanda 48
IQ - Iraq 31
KR - Corea 30
MX - Messico 29
ZA - Sudafrica 27
IE - Irlanda 22
SE - Svezia 21
AR - Argentina 20
AT - Austria 20
TR - Turchia 16
ES - Italia 15
UA - Ucraina 15
EC - Ecuador 12
MA - Marocco 12
IR - Iran 11
KE - Kenya 11
SA - Arabia Saudita 11
CI - Costa d'Avorio 10
MY - Malesia 10
AU - Australia 9
RO - Romania 9
UZ - Uzbekistan 9
JM - Giamaica 8
PK - Pakistan 8
VE - Venezuela 8
CL - Cile 7
EG - Egitto 7
NP - Nepal 7
PH - Filippine 7
BE - Belgio 6
LT - Lituania 6
TN - Tunisia 6
CR - Costa Rica 5
ID - Indonesia 5
LB - Libano 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
NI - Nicaragua 4
PT - Portogallo 4
UY - Uruguay 4
AO - Angola 3
BG - Bulgaria 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
EE - Estonia 3
GT - Guatemala 3
HU - Ungheria 3
NG - Nigeria 3
OM - Oman 3
PE - Perù 3
AZ - Azerbaigian 2
DZ - Algeria 2
ET - Etiopia 2
GE - Georgia 2
GP - Guadalupe 2
IL - Israele 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LV - Lettonia 2
MM - Myanmar 2
MO - Macao, regione amministrativa speciale della Cina 2
PY - Paraguay 2
RS - Serbia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
DJ - Gibuti 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
Totale 8.408
Salva come PNG Salva come JPEG
Città #
Singapore 527
Ashburn 524
San Jose 344
Chandler 185
Hong Kong 178
Moscow 173
Fairfield 163
Palermo 154
Helsinki 123
Zgierz 122
Rome 118
Council Bluffs 116
Munich 101
Beijing 90
The Dalles 88
Los Angeles 86
New York 74
Hefei 71
Dallas 65
Tokyo 65
Seattle 64
Houston 63
Wilmington 61
Ho Chi Minh City 60
Lauterbourg 58
Woodbridge 56
Santa Clara 51
Hanoi 50
Cambridge 49
Ann Arbor 47
Chicago 43
Buffalo 40
Frankfurt am Main 38
Boardman 35
Milan 34
Medford 33
São Paulo 32
London 31
Lappeenranta 24
Orem 23
Warsaw 23
Ludwigshafen am Rhein 21
Princeton 21
Johannesburg 20
Des Moines 19
Lawrence 19
Altamura 18
San Diego 18
Toronto 18
Nuremberg 17
Dublin 16
Montreal 16
Redondo Beach 16
Chennai 15
Seoul 15
Denver 14
Salt Lake City 13
Turin 13
Atlanta 12
Bremen 12
Mumbai 12
Volla 12
Mexico City 11
Stockholm 11
Abidjan 10
Da Nang 10
Haiphong 10
Kitzingen 10
Milazzo 10
Naples 10
Querétaro 10
Rancho Palos Verdes 10
Boston 9
Brooklyn 9
Manchester 9
Memphis 9
Nairobi 9
Paris 9
Phoenix 9
Schiffdorf 9
Amsterdam 8
Baghdad 8
Bexley 8
Bologna 8
Erbil 8
Mascalucia 8
Messina 8
Tashkent 8
Vienna 8
Cairo 7
Elk Grove Village 7
Poplar 7
Rio de Janeiro 7
San Francisco 7
Tampa 7
Turku 7
Verona 7
Biên Hòa 6
Brussels 6
Bắc Ninh 6
Totale 4.939
Salva come PNG Salva come JPEG
Nome #
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 320
Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer 258
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 250
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 238
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer 234
KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting 225
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 212
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 191
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 185
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 181
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 175
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups 172
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 167
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 162
The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer 158
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 157
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? 152
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 150
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal 150
Applications of Platelet Concentrates (PCs) in Regenerative Onco-Urology: A Systematic Review of Literature 149
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 148
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study 147
Cancer of the Thyroid 147
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 146
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 143
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? 142
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 142
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 142
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 140
Molecular tumor board 140
Diabetes and cancer: A critical appraisal of the pathogenetic and therapeutic links 140
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 133
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses 132
Current clinically validated applications of liquid biopsy 131
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic 131
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 130
Scientific Communication and oncology – "The bridge between knowledge and patients" 125
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors 123
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 123
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer 120
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy 117
Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives 116
Potential Applications of PRP-Enhanced Polybutylene Succinate Graft as Vascular Access for Chemotherapy in Oncological Patients: A Systematic Review 115
Circulating cell-free DNA (cfDNA) and extracellular vesicles (EVs) as prognostic and predictive biomarkers in patients with advanced Non-Small Cell Lung Cancer (NSCLC): the LEXOVE prospective study 115
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials 112
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis 110
The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors 110
Liquid biopsy and immunotherapy: is all that glitter gold? 110
Early detection screening: myth or reality? 108
Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code 103
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study 98
Dissecting the nuances of cancer epigenomics in liquid biopsy 98
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review 97
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study 97
Tumor mutational burden on cytological samples: A pilot study 96
TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: An international performance evaluation study 90
Genomics and the early diagnosis of lung cancer 88
Network approach in liquidomics landscape 82
Future perspectives 80
Liquid biopsy: a right tool in a right context? 78
Smaller, Cheaper, Faster: Where Next for Liquid Biopsies? 73
Recent advances in the use of liquid biopsy for the diagnosis and treatment of lung cancer 53
Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer 52
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL 11
Part III – Post-analytical phase 11
Totale 8.831
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022347 0 54 15 9 13 35 18 13 25 49 62 54
2022/2023556 45 91 13 75 39 82 30 64 47 9 44 17
2023/2024494 10 40 28 43 44 81 68 75 19 21 5 60
2024/20251.723 66 94 95 110 78 139 221 142 124 210 214 230
2025/20264.846 402 178 331 480 505 750 696 433 371 277 198 225
2026/2027268 199 69 0 0 0 0 0 0 0 0 0 0
Totale 8.831